Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of TISA-818 injection in ARDS
CTR20232429Phase 2Completed
- Sponsor
- Berrisen Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TISA-818 in acute respiratory distress syndrome (ARDS), sponsored by Berrisen Pharmaceutical. Started Nov 2023; status: completed.
02
Drugs
TISA-818
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on CTR20232429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232429.